Change in visceral fat and total body fat and the effect on cardiometabolic risk factors during transgender hormone therapy.

Maartje KlaverDaan M van VelzenChristel de BlokNota NienkeChantal WiepjesJustine Defreyne Thomas SchreinerAlessandra FisherProf Jos TwiskProf Jaap SeidellProf Guy T'SjoenProf Martin den HeijerRenée de Mutsert

Published in: The Journal of clinical endocrinology and metabolism (2021)

Hormone therapy in trans women and trans men resulted in changes in VAT/TBF, mainly due to changes in total body fat and were unrelated to changes in cardiometabolic risk factors, which suggests that any unfavorable cardiometabolic effects of hormone therapy are not mediated by changes in visceral fat or VAT/TBF.

Keyphrases

risk factors
adipose tissue
insulin resistance
stem cells
fatty acid
polycystic ovary syndrome
type diabetes
pregnant women
cell therapy
hepatitis c virus
hiv infected
mesenchymal stem cells
middle aged
pregnancy outcomes
human immunodeficiency virus
smoking cessation